{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-017885","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.511188+00:00","generated_at":"2026-05-15T11:44:29.603595+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration","bullets":["Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.","Preclinical data for EBD program: 14-40x brain levels in NHPs vs. native antibodies; low anemia risk.","Subcutaneous dosing feasible; IND submission for lead candidate targeted for mid-2027.","Proceeds primarily to support EBD program preclinical work and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-017885","json":"https://secwatch.observer/filing/0001628280-26-017885.json","markdown":"https://secwatch.observer/filing/0001628280-26-017885.md","text":"https://secwatch.observer/filing/0001628280-26-017885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/abos-20260313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:44:29.603595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1112d3f54b5c764ff06a1faf9e57398c29e27914","claim":"Acumen Pharmaceuticals, Inc. entered into Registration Rights Agreement with certain institutional accredited investors valued at registration for resale of the Shares pursuant to a registration statement to be filed with the SEC (effective 2026-03-13).","evidence_excerpt":"In connection with the Private Placement, the Company and the Investors entered into a Registration Rights Agreement, dated March 13, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) no later than two business days after the date on which the Company files with the SEC its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"registration for resale of the Shares pursuant to a registration statement to be filed with the SEC"},{"label":"Effective","value":"2026-03-13"}]},{"claim_id":"9e1ced3bc98f7a9c0e7bf9a713d9466c6909746a","claim":"Acumen Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at 10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million (effective 2026-03-13).","evidence_excerpt":"On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $3.30 per Share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million"},{"label":"Effective","value":"2026-03-13"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}